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Abstract The diagnosis andmanagement of four cases of dermatological disorders, most of which are related to the
endocrine disorder of androgen excess, are presented. Combined oral contraceptives (COCs) may be useful
when well-tolerated hormonal therapy and/or when contraception is required. A female patient with an-
drogenetic alopecia or female pattern balding, without underlying hyperandrogenism, was treated with
ethinylestradiol/chlormadinone acetate (EE/CMA) 0.03mg/2mg for 6 months and experienced stabiliza-
tion of hair loss (case report 1). A patient who had previously received a COC for an irregular menstrual
pattern but again experienced irregular menses and also acne after stopping treatment was diagnosed with
acne associated with polycystic ovary syndrome (PCOS) [case report 2]. After 6 month’s treatment with
EE/CMA 0.03mg/2mg, this patient had fewer acne lesions and became eumenorrheic. A third patient who
had excess hair since childhood was diagnosed with idiopathic hirsutism (no underlying gynecological or
endocrinological disorder was found) and was treated with EE/CMA 0.03mg/2mg (case report 3). Less hair
growth was reported after 6 months’ treatment. Case report 4 describes a patient who presented with
oligomenorrhea and acne. Shewas diagnosedwithPCOSwith acne, seborrhea andmild hirsutism.Treatment
with EE/CMA 0.03mg/2mg for 6 months resulted in improvements in her facial acne, seborrhea and
hirsutism; she also became eumenorrheic. These four cases illustrate that EE/CMAmay be a useful and well
tolerated treatment option in the management of patients with dermatological disorders with or without
hyperandrogenization.
Introduction
Female alopecia, hirsutism, acne and polycystic ovary syn-
drome (PCOS) share a common thread: the endocrine abnor-
mality of hyperandrogenism. Hirsutism and acne, and to a
lesser extent, female alopecia, are all clinical signs of hyper-
androgenization.[1] PCOS is considered primarily to be a syn-
drome of hyperandrogenism.[1] The majority of patients with
hirsutism or unwanted hair growth (75–80%) have PCOS, and
approximately 20–40% of patients with persistent acne only
have PCOS;[1] approximately 10% of women with alopecia also
only have PCOS.[1]
Female androgenetic alopecia, also known as female pattern
baldness (FPB), is a common yet difficult-to-treat condition,[2]
in which even mild cases can have a psychological impact on
patients. FPB is characterized by the progressive miniaturiza-
tion of hair follicles and a decrease in the percentage of anagen
hair.[3,4] Usually there is a diffuse reduction in vertex hair
density with retention of the front hairline.[2] It affects more
than 50% of women over their lifetime, with a prevalence and
severity that increases with age.[4] FPB is a more appropriate
name for the disorder because the role of androgens in the
etiology of the disorder is less certain than in men.[5] Although
most patients with FPB show no signs of hyperandrogenism in
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laboratory testing, their condition improves after treatment
with oral anti-androgens, confirming at least some involvement
of androgens in the pathogenesis of this kind of alopecia.[6,7]
Hirsutism in women is excessive terminal hair appearing in a
male (androgen-dependent) sexual pattern,[8] and is associated
with psychological distress.[9] Approximately half of the cases
of hirsutism in women are due to hyperandrogenism.[8] When
hirsutism occurs in the absence of excess androgen it is termed
‘idiopathic hirsutism’.[8] Hirsutism should be distinguished
from hypertrichosis, which is an increase in body hair beyond
the normal variation of the patient’s reference group, may be
congenital or acquired, and is associated with abnormal hair
growth that is either localized or generalized.[10]
Another clear clinical signal of hyperandrogenism is acne.[11]
Acne lesions (papules, pustules, nodules) form through the
interaction of excess sebum production, sebaceous follicle ob-
struction and bacterium Propionibacterium acnes proliferation
and subsequent inflammation.[12] There is a correlation be-
tween excess sebum production and androgen levels, but the
sensitivity of the sebaceous glands to hormonal stimulation also
contributes to the formation of acne,[9] as increased sensitivity
results in the overproduction of sebum.
PCOS is one of the most common endocrine abnormalities
of women of reproductive age, affecting 6–8% of women
worldwide.[1] PCOS is thought to be associated with an in-
creased risk of infertility, endometrial carcinoma, obesity, type II
diabetes mellitus, dyslipidemia, hypertension and possible car-
diovascular disease.[1] Characteristic features of PCOS are
menstrual disorders (oligo or anovulation), clinical and/or
biochemical signs of hyperandrogenism and polycystic ova-
ries.[11] Not all patients with PCOS have elevated androgen
levels, thus serum measurements of androgen levels are never
the sole criterion for diagnosis.[1]
There is rationale for the use of a treatment that targets the
underlying hyperandrogenism of acne, hirsutism and FPB in
patients with or without PCOS. The four cases presented in this
series highlight the potential use of the monophasic combined
oral contraceptive ethinylestradiol/chlormadinone acetate
(EE/CMA) [Balianca, Belara], in women who would also like
birth control. EE/CMA is approved in Europe for contra-
ception,[13] therefore discussion of its use in these cases is
off-label.
Case Report 1
Mercedes Go´mez Va´zquez, Ramo´n Navarra Amayuelas
A 32-year-old woman, with no other history of clinical sig-
nificance, developed slow and progressive hair loss over a
period of 6 months before her visit. The patient reported a
considerable decrease in hair volume, with no other associated
symptoms except the negative influence of this hair loss on
her self-image and mental state. There was no family history of
hair loss and no history of drug use. Possible factors that may
precipitate or exacerbate alopecia, including chronic illness,
nutritional alteration, metabolic and endocrinolic alteration,
recent surgical intervention and medical treatment, were
excluded.
Clinical examination showed hair loss in the median line
of the head, with a Christmas tree pattern of hair distribu-
tion, Olsen scale type II, with greater involvement of the cen-
tral line and conservation of the frontal hair implantation
line (figure 1). Pull test was negative. No signs of excess sebum
production were observed. The patient had no present termi-
nal hair loss from other locations and no nail changes. Efflu-
vium was ruled out by the absence of a diffuse loss of scalp
hair, the absence of laboratory abnormalities, and no history of
drug use. Laboratory testing included a hemogram (complete
blood count), assessment of iron and ferritin levels, and of
the following hormones: thyrotropin hormone, thyroid T4,
follicle-stimulating hormone (FSH), luteinizing hormone (LH),
prolactin, estrogen, free testosterone and dehydroepiandro-
sterone sulfate (DHEAS). All test results were within the
Fig. 1. Frontovertical alopecia or hair loss with a triangular or Christmas tree
pattern.
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normal range. Gynecological examinations showed no gyne-
cological conditions.
The patient was diagnosed with FPB with no underlying
endocrine disorder. Treatment with oral EE/CMA 0.03mg/
2mg plus daily application of topical minoxidil 2% in a 2mL
aqueous solution was initiated. After 3 months, minoxidil
treatment was suspended because of local adverse drug re-
action, erythema and irritation. After 6 months’ treatment with
EE/CMA, the patient reported subjective improvement in hair
loss and mental state. Examination showed stabilization of the
hair loss process (Olsen type II). The pull test remained neg-
ative. Figure 2 shows hair regrowth after 1 year of treatment
(Olsen type I).
Case Report 2
Marta Lamarca, Laura Baquedano
The female patient was 29 years old with a history of chronic
ferropenic anemia receiving oral ferrotherapy, but with no
other significant medical or surgical history. Since menarche at
the age of 13 years the patient had had an irregular menstrual
pattern (3–4/45–79) for which she received ethinylestradiol/
cyproterone acetate 35 mg/2mg treatment, which resulted in
eumenorrhea. At age 28 years contraceptive treatment was
voluntarily stopped. After 1 year without contraceptive treat-
ment her menstrual irregularity returned and the patient re-
ported an increase in dermatological lesions.
Physical examination revealed facial acne with over 20 in-
flammatory lesions and over 30 non-inflammatory lesions
(blackheads in the frontal, nasal and chin area). There was no
presence of hirsutism. Bodyweight had increased by 6 kg since
the last check-up 1 year previously when the patient was aged
28 years, i.e. when oral contraceptive treatment was voluntarily
stopped. Gynecological examination showed that the genitalia,
vagina and uterine cervix were of normal appearance. Biman-
ual examination revealed the uterus in anteflexion was of nor-
mal size and morphology, and no adnexal masses were felt.
Transvaginal ultrasonography revealed that the uterus in
anteflexion measured 73 · 45 · 48mm, the endometrium was
8mm and the myometrium was homogeneous. Both ovaries
had over 12 follicles each (each follicle 2–9mm in size). There
was no fluid in the pouch of Douglas. Hormone serum levels
were within the normal range (17 beta estradiol 49 pg/mL,
progesterone 1.1 ng/mL, LH 18.27mIU/mL, FSH 6.61mIU/mL)
except for androstenedione (7.3 ng/mL; normal range
0.30–3.30 ng/mL). The patient had had irregular menstruation
since discontinuing oral contraceptive treatment, and she had
not been menstruating for 3 months at the time of the labora-
tory tests.
The patient was diagnosed with acne associated with PCOS.
Treatment with EE/CMA 30 mg/2mg was prescribed. After
6 months, her acne improved (less than five inflammatory le-
sions; less than 15 non-inflammatory lesions).The patient was
eumenorrheic (menstrual pattern 2–3/28) and her bodyweight
stabilized, 77.4 kg before treatment and 75.1 at last measurement.
Case Report 3
Sebastia´n Romero Ruiz
A 19-year-old female patient reported excess hair since
childhood, which had increased since puberty, but no rapid
increase before the visit was reported. The patient was nulli-
parous, experienced menarche aged 13 years and did not report
menstrual disorders (menstrual pattern 4/28–35). The patient’s
mother had excess hair, treatedwith laser hair removal, and had
experienced two pregnancies and normal childbirths. The pa-
tient had no other significant personal or familymedical history.
The patient’s excess hair was assessed using the Ferriman–
Gallwey scoring system, with a total score of 16 (maximum 36),
distributed as follows: upper lip 3, chin 3, thorax (periareolar) 1,
abdomen 2, pubis 2, arms 2, legs 1, upper back 1, lower back 1.
No acanthosis nigricans was found. Her body mass index was
23. Manual gynecological examination results were normal,
Fig. 2. Hair regrowth after 1 year of treatment showing slight improvement
with partial recovery of central line.
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with no hypertrophy of the clitoris or inguinal mass. The gy-
necological ultrasound revealed a normal genital system, with
no suggestion of polycystic ovaries. Laboratory, hemogram
and coagulation test results were within the normal range.
The following serum hormone levels were assessed in the initial
cycle and were all normal: prolactin, thyroid hormones,
FSH, LH (LH:FSH ratio of 1.5), estradiol, testosterone, an-
drostenedione, dehydroepiandrosterone, DHEAS, 17.OH.
progesterone. Free urine cortisol levels were also normal.
We diagnosed the patient with idiopathic hirsutism. Treat-
ment was initiated with oral EE/CMA 0.03mg/2mg. After
6 months’ treatment, the Ferriman–Gallwey score decreased
to 11 (upper lip: 2, chin 1, thorax, 1 abdomen 1, pubis 2, arms 2,
legs 1, upper back 0, lower back 1), with clear improvements in
the facial area.
Case Report 4
Eduardo Vilar-Checa, Maria D. Iniesta
A 20-year-old woman presented in July 2010 with oligome-
norrhea (menstrual pattern 3/35–50) and progressive acne since
menarche (13 years). The patient was not taking any medi-
cations. The patient’s menstrual pattern was 3/35–50 and her
longest period of amenorrhea had been 4months. There was no
history of an abnormal pap smear and the last one was obtained
in July 2010. The patient denied pain with menstruation or
intermenstrual bleeding. The patient also sought counselling
for an appropriate contraceptive method. The patient and her
parents’ medical history were otherwise unremarkable.
Dermatological examination revealed the presence of acne,
especially on her face and only to a slightly mild degree on her
back; the lesions were mainly papulopustular lesions, partic-
ularly on her face. She also showed slight hirsutism in the form
of dark terminal hairs involving the chin. A significant increase
of the seborrheic secretion on the face was also noticed upon
clinical assessment.
There were no other signs of virilization. Gynecological
examination revealed that the vulva, urethra, vagina and cervix
were normal. On bimanual examination, no nodularity, mass
or tenderness was noted on the uterus or ovaries. The uterus
was normal in size, shape and mobility and no adnexal masses
were noted. The cul-de-sac was smooth. Breasts were without
dominant masses, skin changes or nipple discharge. Physical
examination suggested an otherwise healthy individual (body
mass index 22.86).
Gynecological ultrasound revealed a normal-sized uterus in
anteversion. Both ovaries had multiple follicles (14 follicles of
4–6mm in diameter in the right ovary and 16 of the same di-
mensions in the left ovary). The volume of both ovaries was
over 10mL and the ovarian stroma was hyperechogenic. A
complete blood count, coagulation testing and laboratory
testing (including glucose and cholesterol levels) showed nor-
mal ranges, including a euglycemic–normoinsulinemic profile.
Baseline hormone levels on the third day of the menstrual cycle
were as follows: FSH 3.25mUI/mL, LH 10.90mUI/mL (with a
ratio LH:FSH >3), estradiol 60 pg/mL, prolactin 15.10 ng/mL
(normal values 4.50–40), total testosterone 0.59 ng/mL (normal
values 0.20–0.90), DHEAS 270 mg/dL (normal values 10–340)
and androstenedione 6.02 ng/mL (normal 0.30–3.3).
The patient was diagnosed with PCOS. Treatment with
EE/CMA 0.03mg/2mg was initiated. After 6 months’ treat-
ment, there were slight improvements in acne with the number
of acne lesions decreased almost to half on her face, and a
marked decrease in seborrheic secretion and facial hirsutism.
The patient denied any laser hair removal or waxing of her face
subsequent to treatment initiation. Androstenedione levels
decreased from 6.02 ng/mL to 3.33 ng/mL. The patient’s men-
strual cycle control improved, and cycles normalized without
spotting at any time (menstrual pattern 3/28). At 10 months
after treatment initiation, the patient remains on treatment with
EE/CMA.
Conclusions
Differential diagnoses were ruled out in each case reported.
The patient in case 1 had FPB in the most commonly reported
pattern of hair loss in women: the Christmas tree pattern, first
described by Olsen, in which there is intensive hair loss in the
median line of the head that progressively increases towards the
frontal area.[7] Diffuse telogen effluvium (the patient had nor-
mal iron/ferritin and thyroid hormone levels),[5] alopecia areata
(absence of diffuse or patches of hair loss on the scalp, absence
of terminal hair loss in other locations, abscense of nail changes
[pitting] and a negative pull test), underlying hyperandrogenism
(no clinical signs of excessive body hair growth, seborrhea,
acne,[4] and testosterone levels were normal) and PCOS (no
hyperandrogenism and no gynecological or menstrual abnor-
malities)[4] were all ruled out. In case 3 the patient was diagnosed
with idiopathic hirsutism without underlying hyperandrogenism.
The patient had not been using any medication nor did she
use any cosmetic cream containing hormones. As idiopathic
hirsutism may be caused by increased 5a-reductase activity in
the pilosebaceous unit,[5] and thus ‘increased sensitivity’ to
androgens, hirsutism can exist in the absence of other signs of
virilization (as found in our patient). The patients in cases 2 and
4 were diagnosed with PCOS according to the requirements for
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diagnosis outlined in the Rotterdam European Society of Human
Reproduction and Embriology/American Society for Reproduc-
tive Medicine PCOS consensus guidelines,[1] with the diagnosis
based on the following: clinical signs of hyperandrogenization
(acne in both cases, mild hirsutism in case 4); biochemical signs
of hyperandrogenization (direct evidence in case 2 of elevated
androgen serum levels and supporting evidence in case 4 of
elevated androstenedione levels and elevated LH levels and an
LH:FSH ratio, which support evidence for the diagnosis);[1,3]
oligo or anovulation (amenorrhea in case 2 [a sign of anovula-
tion] and irregular periods in case 4) and ultrasound imaging
showing polycystic ovaries. The ferrotherapy administered to
the patient in case 2 would not have interfered with the results
of laboratory tests. In both patients with PCOS, androgen-
secreting neoplasms could be excluded because of the absence
of frank virilization and lack of rapid onset of hyperandro-
genism.[3] Neither patient had acanthosis nigricans, a cutaneous
sign of hyperinsulinemia and thus were not suspected to have
severe insulin resistance, which may co-occur with hyperandro-
genism.[3] Finally, rare possible causes of excess androgen, for ex-
ample congenital adrenal hyperplasia, androgen-secreting tumors
and Cushing’s syndrome were not suspected based on clinical and/
or laboratory examinations and were ruled out in cases 1, 3 and 4.
Among the pharmacological treatments available tomanage
or treat the dermatological disorders in the patients in our case
series, a rational treatment choice would be hormonal therapies
that target androgen excess (in which androgen excess is found,
e.g. in acne)[9] or those that target pilosebaceous unit sensitivity
to androgens (in which increased 5a-reductase activity is found,
e.g. in idiopathic hirsutism).[14]
Oral hormonal therapies investigated for female androgenetic
alopecia have had varied success. The 5a-reductase inhibitor
(a testosterone conversion blocker) finasteride does not appear
to be effective, at least in postmenopausal women (at a dose of
1mg).[15-17] The oral anti-androgens (androgen receptor antag-
onists) spironolactone[18] and cyproterone acetate (alone or
when given in combination with an estrogen)[18-20] have been
shown to be effective in limiting the progression of hair loss or
improve hair growth, and have been used off-label for many
years despite a lack of evidence from well-designed studies. The
use of anti-androgens requires the use of good contraception
because of the risk of feminization of a fetus.[21] Evidence of
their use fromwell-designed studies is lacking. Limited evidence
suggests hormonal therapy is helpful even in patients with FPB
with normal hormone levels.[2] Currently, the only approved
agent for female androgenetic alopecia is a non-hormonal
therapy (minoxidil).[2] None of the pharmacological treatments
for FPB result in full hair recovery, and they are therefore used
indefinitely to prolong their effect.[22] Similarly, the manage-
ment of hirsutism requires ongoing treatment with cosmetic
(e.g. topical eflornithine hydrochloride) and physical measures
(such as electrolysis, laser hair removal) and/or hormonal
therapy.[8] Anti-androgens (e.g. spironolactone, cyproterone
acetate) have been investigated in this indication but not in
randomized controlled trials, and again, their use is limited by
the potential for feminization of male fetuses.[8,21] Combined
oral contraceptives (COCs; combination of an estrogen and a
progestin) are the first line of pharmacological treatment of
hirsutism, particularly in young women who do not want to
become pregnant.[21] COCs that may be used include those with
low androgenic activity, such as ethinylestradiol in combina-
tion either with drospirenone (Yasmin), norgestimate (Ortho-
Cyclen) or ethynodiol diacetate (Demulen 1-50).[8] Cyproterone
has also been combined with ethinylestradiol in a contraceptive
(Dianette) and is approved for use in moderately severe
hirsutism, but is associated with body weight gain, reduced
libido and breast tenderness.[23]
Two patients (cases 2 and 4) had PCOS and sought treat-
ment for their acne (one of these patients also wanted birth
control); treatment for associated fertility problems/anovula-
tion was not requested.
Acne may be treated with topical and/or systemic drugs.
Topical agents include retinoids, antibiotics or benzoyl per-
oxide. Systemic agents include antibiotics or retinoids, alone
or in combination with COCs. COCs are considered first-
line treatment in women with acne who desire contracep-
tion provided no contraindications exist;[24] compared with
placebo, COCs reduce acne lesion counts, lesion severity and
self-assessed acne.[25] COCs containing a progestin with anti-
androgenic effects or an anti-androgen (e.g. cyproterone, dro-
spirenone and chlormadinone) should be considered in the
first place.[26] Numerous studies support the use of COCs com-
posed of low-dose estrogens (defined as ethinylestradiol <50 mg)
plus anti-androgenic agents or progestins with anti-androgenic
properties.[27-33]
EE/CMA is composed of a low-dose estrogen component
(ethinylestradiol) and an anti-androgenic component (chlor-
madinone acetate), and was selected as an appropriate hor-
mone therapy for each of the patients in this case series because,
like other COCs, the estrogen component reduces androgen
levels via their action onother hormones (LH,FSH, sex hormone-
binding globulin), and anti-androgenic progestins have an-
drogen receptor and/or 5a-reductase inhibitory activity.[34]
EE/CMA has not been investigated in clinical trials in patients
with FPB or hirsutism, but subgroups of patients receiving
EE/CMA in trials evaluating its efficacy in the treatment of
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acne and/or seborrhea have reported beneficial effects (as de-
scribed in detail in the accompanying review article.[29,35,36] All
four patients were successfully treated with EE/CMA. It was
also well tolerated; no treatment-related adverse events were
reported by any of the patients in this case series.
EE/CMA has a favorable hormone profile, and appears to
improve acne and other dermatological conditions; it is also
well tolerated and patient compliance is generally high.[27,29,31,33]
Although confirmatory evidence of its efficacy in hirsutism and
androgenetic alopecia in large, well-controlled studies is required,
EE/CMAmay be a valuable option among available COCs in the
management of hirsutism, androgenetic alopecia and acne.
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